Isomorphic Labs– tag –
-
Google DeepMind’s AlphaFold 3 Achieves Unprecedented Accuracy in Predicting Molecular Interactions, Driving AI-Discovered Drugs to Phase III Trials
New Market Pitch Unknown Overview AI drug discovery is now fully functional in structural prediction, molecular design, lead optimization, and protein engineering. Google DeepMind and Isomorphic Labs' AlphaFold 3 demonstrates superior ac... -
Isomorphic Labs and Recursion Pharmaceuticals Forge Major AI Drug Discovery Alliances with Pharma Giants
flcube.com International Overview Isomorphic Labs, an Alphabet subsidiary, has secured significant AI-driven drug discovery partnerships with Eli Lilly and Novartis to identify novel small molecule therapeutics for undisclosed targets. C... -
PitchBook Analysis: Rebounding Biotech Funding Expected to Drive CDMO Growth in 2026, Focus on Complex Modalities
BioSpace USA Overview This article provides an overview of a PitchBook analysis report. According to PitchBook, biotech venture capital funding in the first half of 2026 surpassed $10 billion, driven significantly by Isomorphic Labs' $2.... -
K-38 Consulting Report: Biotech VC Funding Rebounds to Over $9.1 Billion in H1 2026, While Early-Stage Investment Hits Pre-Pandemic Low
WBOC (Press Release) USA Overview This article presents an overview of a market research report by K-38 Consulting. The report indicates that biotech venture capital funding in the first half of 2026 exceeded $9.1 billion, reaching its h... -
AI Biotechs Drive ‘Fail-Fast’ Drug Development in Biopharma, Powered by DeepMind’s AlphaFold
BioSpace USA Overview AI-centric biotechs like Isomorphic Labs and Generate Biomedicines are leveraging Google DeepMind's AlphaFold and proprietary 'dataverses' to propel a 'fail-fast' approach in drug discovery through in silico experim... -
Isomorphic Labs: AI-Designed Drugs Head to Human Trials, Reshaping Pharma’s Future
Wired USA Overview Isomorphic Labs, a Google DeepMind spin-off, is on the verge of commencing human clinical trials for drugs entirely designed by artificial intelligence. Leveraging its foundational AlphaFold system, the company aims to... -
Isomorphic Labs Secures $2.9 Billion in Partnerships with Eli Lilly and Novartis, Validating AI Drug Discovery Platform
GeneOnline Taiwan Overview Isomorphic Labs, a Google DeepMind spin-out, has solidified its AI drug discovery platform's value through significant partnerships totaling $2.9 billion with Eli Lilly ($1.7B) and Novartis ($1.2B). Concurrentl... -
AI Drug Discovery Cuts Development Time to 18 Months, Insilico Medicine Achieves 99% Cost Reduction for Novel Candidates
BCC Research USA Overview AI is dramatically accelerating drug discovery, shortening the timeline from a decade to under 18 months, with Insilico Medicine identifying a drug candidate for just $2.6 million—a 99% cost saving. This rapid a... -
From Silicon to Synapse: AI Giants Target Pharma, Yet Clinical Timelines Threaten Capital Returns
36Kr China Overview Major AI players, including Anthropic, OpenAI, and Google's Isomorphic Labs, are rapidly entering the life sciences, leveraging AI to accelerate early drug discovery. However, the inherently long timelines for clinica... -
AI Drug Discovery Enters “Clinical Proof Era” in 2026 with Insilico’s Rentosertib in Phase 3 and Isomorphic Labs’ IsoDDE Nearing Clinical Entry
PharmaADC Unknown Overview The article highlights 2026 as the "era of clinical proof" for AI drug discovery, exemplified by Insilico Medicine's AI-developed rentosertib entering Phase 3 trials for idiopathic pulmonary fibrosis (IPF) in J...
12